Overcome Top Challenges in Analytical Method Development and Validation
|
|
- Marjory Freeman
- 6 years ago
- Views:
Transcription
1 Overcome Top Challenges in Analytical Method Development and Validation Q. Chan Li, Ph.D. Analytical Development US, Boehringer Ingelheim Pharmaceuticals, Inc. IVT Analytical Method Validation, San Diego, CA, 2-4 December 2014
2 Outline Ask three questions before method development and validation Top challenges for method development (MD) Top challenges for method validation (MV) IVT Analytical Method Validation, San Diego, CA, 2-4 December
3 Questions to ask before method development and validation What is the stage of product/clinical development (Preclinical, Phase 1, Phase 2, Phase 3, QCcommercial)? Where in the process/product development is the method used? (process monitoring, in-process testing, release testing, stability testing) What is the purpose of the method (assay, dissolution, impurity analysis, genotoxic impurity )? IVT Analytical Method Validation, San Diego, CA, 2-4 December
4 Top challenges for method development (MD) How to select target analytes (impurities) for method development? Sample preparation and stability issues Method development screening (column types, mobile phases, ionic strength, ph, temperature) Chromatographic difficulties (critical pair, peak tailing ) Method conversions (UHPLC to HPLC, HPLC-UV to HPLC-MS compatible) Separation of multiple stereoisomers Quantitation limits and difficult detection IVT Analytical Method Validation, San Diego, CA, 2-4 December
5 Top challenges for method development - How to select target analytes (impurities) for method development? Content uniformity, Dissolution, HPLC Assay: major component (e.g., API, DS) The API is separated from impurities. Aim for a short run HPLC impurity analysis Impurities reasonably expected based on knowledge of the process and product Work with DS / DP manufacture units to construct a list of impurities Potential process impurities, byproducts, including stereoisomers Potential degradation products Actual impurities Genotoxic impurities (GTI) Now called DNA reactive (mutagenic) impurities by ICH M7 (use GTI for convenience) GTI is separated from all other components IVT Analytical Method Validation, San Diego, CA, 2-4 December
6 Top challenges for method development - How to select impurities? Case 1, Example 1: 11 potential impurities X OH OH R 1 OMe R 1 OMe + O R O 2 N N R 2 R 3 R 1 R 2 R 4 N OH OMe O + R 1 R 2 X N OH OMe O A 676 R 1 R 2 R 3 N O O OMe R 1 R 2 R 4 N O O OMe R 1 R 2 X N O O OMe 678 B C API R 1 R 2 R 3 N 790 O O OH R 1 R 2 R 4 N G O O OH R 1 R 2 X N H O O OH R 3 R 1 OH OH R 1 R O 2 N D R 2 R 4 N E OH OH O R 1 R 2 X N F OH OH O 6
7 Top challenges for method development - Sample preparation and stability issues Solubility For sparingly water soluble materials, dissolve in organic solvent(s) first, then dilute with diluent (or water). Or use diluent with high organic content Sonication, shaking Excipients can make DP sample preparations more challenging Solubilization, sonication, shaking, centrifugation, filtration Insufficient materials available in early stages of development Extraction to enrich very low levels of analytes, e.g., GTI mesylates Derivatization Stability Refrigeration Solvent selection (recent case uses 80/20 methanol/water to minimize hydrolysis) Protection from heat, humidity, light Need to validate recovery (accuracy) for sample preparations IVT Analytical Method Validation, San Diego, CA, 2-4 December
8 Top challenges for method development - Sample preparation and stability issues: Case 2 - Capsule case API is sparingly soluble in water Capsules are color coded Diluent: 0.1% TFA in acetonitrile/water 70/30 (v/v) Capsule solution preparation Place capsules in a flask and add diluent to 80% of the volume Ultrasonicate with periodic swirling for approximately 30 minutes Place flask on reciprocating shaker for 30 min Dilute to volume mark with diluent. Centrifuge to separate insoluble colorants from clear supernatant Pipet supernatant and dilute to desired concentration Protect sample solutions from light as much as possible during preparation IVT Analytical Method Validation, San Diego, CA, 2-4 December
9 Top challenges for method development - Sample preparation: Case 1: Insufficient materials 11 potential impurities for API 790 (from Case 1) Only 4 authentic materials available Material Compound Major Impurities # ~ 1% A ~ 2% 676 # ~ 1% B ~ 2% C # 3 DS 790 ~ 1% G ~ 2% H # 4 (hydrolysis of 678) D ~ 1% E ~ 1% F HPLC selectivity solution 1:1:1:1 mixture of materials # Inject selectivity solution, not 4 individual material solutions, for MD screening conditions After HPLC conditions are finalized, inject 4 individual material solutions Peak assignments based on retention times, relative peak intensities, and structures Peak assignments to be confirmed by LC-MS IVT Analytical Method Validation, San Diego, CA, 2-4 December
10 Top challenges for method development - MD screening: Case 1 - UPLC MD screening by using Fusion AE Columns Columns 0.05% Trifloroacetic acid (TFA) in water, ph 2 20 mm Ammonium bicarbonate buffer, ph 8 Acquity UPLC HSS T3, 1.8 µm, 2.1x50 mm Acquity UPLC BEH phenyl, 1.7 µm, 2.1x50 mm Acetonitrile (ACN) Acquity UPLC BEH Shield RP18, 1.7 µm, 2.1x50 mm Methanol (MeOH) Zorbax SB-C18, 1.8 µm, 2.1x50 mm % B in 10 min, 0.6 ml/min, 220 nm, 40 C % B in 12 min, hold 100% B for 3 min Waters UHPLC
11 Top challenges for method development - MD screening: Case 1- Optimal conditions from screening C18 columns with MeOH / 0.05% TFA-H 2 O
12 AU MD Screening - MD screening: Case 1 Convert UHPLC to HPLC Zorbax SB-C18, 2.1 x 50 um, 1.8 µm XBridge C18 column, 2.1 x 50 um, 2.5 µm XBridge C18 column, 3.0 x 100 um, 3.5 µm Agilent 1100 XBridge C18, 3.0 x 100 mm, 3.5 µm 220 nm, 8 µl injection, 0.6 ml/min A = 0.05% TFA in water, B = MeOH GE: % B in 12 min, hold for 3 min Column 40 C Minutes
13 Top challenges for method development - MD screening: Case 1 DryLab 3-step gradient simulation XBridge C18, 3.0 x 100 mm, 3.5 µm A = 0.05%TFA-H 2 O, B = MeOH
14 Top challenges for method development - MD screening Case 1 : three -step gradient experiment Agilent 1100 Xbridge C18, 3.0 x 100 mm, 3.5 µm 220 nm, 8 µl injection, 0.6 ml/min A = 0.05% TFA in water, B = MeOH Column 40 C
15 Top challenges for MD - MD screening: Case 1 DryLab two -step gradient simulation XBridge C18, 3.0 x 100 mm, 3.5 µm; MeOH and 0.05%TFA-H 2 O
16 AU Top challenges for method development - MD screening: Case 1 two -step gradient experiment Ignore the imp in an Impurity Agilent 1100 XBridge C18, 3.0 x 100 mm, 3.5 µm 220 nm, 8 µl injection, 0.6 ml/min A = 0.05% TFA in water, B = MeOH Column 40 C Minutes
17 Top challenges for method development Case 1: Peak ID by HPLC retention times, peak intensities, structures
18 Top challenges for method development Case 1: Peak ID confirmed by LC-MS (exact match) Method developed in 7 days! Final HPLC Conditions: Mobile Phase: A: 0.05% TFA in water B: methanol Column: XBridge C18, 3.0 x 100 mm, 3.5 µm Column temperature: 40 C Injection: 6 µl Flow rate: 0.6 ml/min Wavelength: 220 nm Run time: 23 min Gradient: Time (min) %B
19 Top challenges for MD - MD screening: Case 3 - A recent case Mobile Phases Aqueous (3): Columns Agilent Eclipse Plus C18 (2.1 x 50 mm, 1.8 µm) 0.1% TFA, ph 2 Waters Xbridge C18 (3 x 50 mm, 2.5 µm) 10 mm Ammonium Acetate, ph 4 Agilent Zorbax SB-Aq (2.1 x 50 mm, 3.5µm) 10 mm Ammonium Acetate, ph 6.8 Agilent Eclipse Plus Phenyl-Hexyl (2.1 x 50 mm, 1.8 µm) Organics (2): Acetonitrile, Methanol Waters Aquity UPLC HSS T3 (2.1 x 50 mm, 1.8 µm) Agilent Zorbax SB C8 (2.1 x 50 mm, 1.8 µm) 19
20 Top challenges for MD - MD screening: Case 3 - A recent case Convert from UHPLC column to HLPC column and change to phosphate buffer for late-stage development Parameter Condition Mobile Phase A 0.2 % Diammonium hydrogen phosphate ph adjusted to 7 with phosphoric acid Mobile Phase B Acetonitrile Column Agilent Zorbax SB-AQ, 3.5 µm, 3 x 100 mm Column temp 25 0 C Flow 0.6 ml/min* Gradient 0-95% B in 20 min (1 min initial hold)* Wavelength 225 nm Injection volume 5 µl* *Final method conditions: 1ml/min, 80% B final gradient, 15 µl injection 20
21 Top challenges for method development -MD screening: Case 3 - conversion from HPLC-UV to HPLC-MS AU AU % (NH 4 ) 2 HPO4, ph % Diammonium hydrogen phosphate, ph 7 SM 2 Imp 2 Potential Imp SM Imp 1 H2O2 deg Imp Minutes Equivalent Selectivity mm 10mM ammonium Ammonium Acetate, acetate, ph ph SM 2 Imp 2 Potential Imp SM Imp H2O2 deg Imp Minutes 21
22 Top challenges for method development - Separation of multiple stereoisomers in DS Case 4 API 877 has 3 chiral centers 8 stereoisomers Two chiral precursors 818 and has one chiral center 121 has two chiral centers Develop a control strategy as per ICH Q11 Chiral purities of both precursors are controlled Precursor 818 consistently shows enantiomer <0.05% 4 API stereoisomers (chart) Still add the stereoisomer resulting from 818 enantiomer 5 API stereoisomers Chiral HPLC method targets 5 compounds: 937, 938, 408, 409, and 877 (API) API 877 (3 chiral centers, CC) 8 isomers 818 (1 CC) Theory: 2 isomers Reality: 1 isomer 4 isomers 121 (2 CC) Theory: 4 isomers 22
23 Top challenges for method development - Separation of multiple stereoisomers Case 4 Variables Weak Solvent Strong Solvent Temperature Column Heptane 1-Propanol 25 C IA (4.6 x 150 mm, 3 µm) 0.1% DEA in Heptane* 2-Propanol 40 C IB (4.6 x 150 mm, 5 µm) IC (4.6 x 150 mm, 3 µm) Ethanol ID (4.6 x 150 mm, 3 µm) IF (4.6 x 150 mm, 3 µm) *For acidic samples replace diethylamine with trifluoroacetic acid Constants: Injection volume Mobile phase gradient, 20%-90% Strong solvent in 30 min, 1 ml/min Rapid Chiral HPLC Method Development Using Fusion Software 25 November
24 Top challenges for method development - Separation of multiple stereoisomers Case 4 IC Column, Ethanol, 40 C The weak solvent is Heptane with 0.1% diethylamine IB Column, 2-Propanol, 25 C IC Column, 1-Propanol, 25 C 24
25 Top challenges for method development - Case 4 - Final chromatographic conditions Chiracel IC column, 4.6 x 150mm, 3µm A = Heptane with 0.1% diethylamine, B = 1-propanol (B) 40%-90% B in 30 min, 1.0 ml/min, 40 C 25
26 Top challenges for method development - Difficult detection for LC methods Analyte type Practical solutions Analytes with very different max Non-chromophoric analytes, GTI with low QL (ppm) Non-chromophoric analytes Making non-chromophoric analytes suitable for UV detection Very low levels of impurities (GTIs) Different UV wavelengths MS detector Charged aerosol detector (CAD) Evaporative light scattering detector (ELSD) Derivatization Sample enrichment (e.g., extraction, evaporation) IVT Analytical Method Validation, San Diego, CA, 2-4 December
27 Top challenges for method development - Difficult detection: Case 5 - using CAD detection R 1 NH NH 2 + IN 2 (not shown) (poor chromophore) R 1 N Cl R 2 IN 1 R 1 and R 2 are aliphatic groups R 2 IN 3 N Challenges in GC FID IN 3 (parent), IN 1 and IN 2 are salts, difficult to volatilize without converting them to free bases Free base IN 1 showed poor chromatography with severe tailing; unacceptable recovery Derivatization to minimize the tailing is difficult Challenges in HPLC-UV There is NO single wavelength (e.g., 195 nm) appropriate for detecting all 3 Impurity analysis by area percent is not accurate HPLC-UV method needs individual reference materials Corona Charged Aerosol Detector (CAD) seemed to offer a better alternative 27
28 mv Top challenges for method development - Difficult detection: Case 5 : HPLC CAD final conditions Agilent SB-Ag, 4.6 x 150 mm, 3.5 µm CAD, pressure 3.5 psi, range 100mP Heater temp: off; sampling rate 10 15µL injection, 1.2 ml/min A = 0.1% HFBA in 98/2 (v/v) water/ MeOH; B = Acetonitrile; Column 40 C Minutes 5 6 Selectivity solution containing 100% APISM, 0.5% of IN 1 and IN Peak Peak Name Number 1 IN1 2 RRT RRT RRT IN3 6 RRT IN2 8 RRT RRT RRT RRT Background Peak 13 RRT 1.50 Have successfully used HPLC-CAD to analyze intermediates, amino acids, counter ions, co-crystal components. 28
29 Top challenges for method development - Difficult detection: Case 6: using derivatization A limit test for formaldehyde in a BI DS (J. Chrom. Sci. 2008, 46 (6), pp ) Derivatization: HCHO + 2,4-dinitrophenylhydrazine (DNPH) Schiff base Choose a well established chemical reaction mau *DAD1, (838 mau, - ) Ref=2.924 & of D DNPH ACE C8, 150 mm x 4.6 mm, 3 um 45:55 acetonitrile /water (v/v) 1.0 ml/min, = 360 nm nm mau *DAD1, (72.1 mau,apx) Ref=6.539 of D HCHO-DNPH *DAD1, (350 mau, - ) Ref=7.597 & of SIG10002.D nm QL =0.3 ppm F E D C B A mau BI DS RT (min): DNPH, 3.82; HCHO-DNPH, 6.37; BI DS, IVT Analytical Method Validation, San Diego, CA, 2-4 December 2014 nm A. Mobile Phase (Blank); B. HCHO (Blank); C. DNPH; D. BI DS; E. Derivatization standard at QL 0.3 ppm F. Derivatization sample (spiked with formaldehyde, ~3.33 ppm) 29
30 Top challenges for method validation (MV) Guidances How much validation needs to be done? Japanese regulatory Authorities (MHLW) s special requirement for intermediate precision Bias in linearity Mass imbalance Recovery out of range Robustness issues (Workshop S4) Method verification (Workshop S11) Revalidation (Workshop S14) IVT Analytical Method Validation, San Diego, CA, 2-4 December
31 Top challenges for method validation - Guidances and recent references ICH Q2(R1): Validation of Analytical Procedures: Text and Methodology (Step 4, November 2005) FDA Reviewer Guidance on Validation of Chromatographic Methods (November 1994) USP/NF General Chapter <621> Chromatography General Chapter <1224> Transfer of Analytical Procedures General Chapter <1225> Validation of Compendial Procedures General Chapter <1226> Verification of Compendial Procedures Lifecycle approach (recent) D. Chambers et al., GMPs for Method Validation in Early Development: An Industry Perspective (Part II), Pharm. Technol. 36 (7) (2012) FDA Draft Guidance for Industry: Analytical Procedures and Methods Validation for Drugs and Biologics, February 2014 CMC USP Validation and Verification Expert Panel on Lifecycle Management of Analytical Procedures: Method Development, Procedure Performance, Pharmacopeial Forum(PF) 39(6) IVT Analytical Method Validation, San Diego, CA, 2-4 December
32 Top challenges for method validation - How much validation needs to be done? ICH Q2, FDA review guidance, and USP general chapters are for phase 3 and registration for NDA, ANDAs, BLAs, and DMFs For Phase 3 and registration, intermediate precision validation design that also meets Japanese Regulatory Authorities (MHLW)) s special requirement Day Analyst Apparatus Column Preparation 1 A A A 2 2 A B A 2 3 A A B 2 4 (1) B B A 2 5 (2) B A B 2 6 (3) B B B 2 Staged approach to clinical phases 1-2 Do not validate intermediate precision and robustness (except solution stability) Select fewer impurities for linearity, precision, accuracy validation Scale back extent of accuracy validation, e.g., 2 x 2 instead of 3 x 3 IVT Analytical Method Validation, San Diego, CA, 2-4 December
33 Top challenges for method validation - How much validation needs to be done? Recent, broad thinking of lifecycle approach - FDA draft guidance on MV (2014) Revalidation, alternative method, method comparability study, method transfer Workshops S4, S11, S14 Method qualification (or qualified methods) IQ paper (2012) Scientific sound, reliable methods used for characterization work, such as reference standards, IPT, GLP analysis, the scientific prediction of shelf-life Not used for GMP release of clinical materials Method verification USP general chapter <1226> Assessing the suitability of a compendial test procedure under the conditions of actual use Verification is not required for basic compendial test procedures, such as LOD, ROI, various wet chemical procedures (e.g., acid value), ph measurements. BUT consideration is given to any new or different sample handling or solution preparation requirements IVT Analytical Method Validation, San Diego, CA, 2-4 December
34 Top challenges for method validation (MV) Bias in linearity Bias is the intercept on the Y-axis (response like peak area) Co-elution of components with very different responses at a given Purity of the analyte is not accurately determined Background interference When assay and impurity are in one method Prefer to use the assay standard response for calculating assay and impurities When the assay standard response is not linear from 0.05% (QL) - 120%, then an impurity standard (e.g., at 0.5%) needs to be used IVT Analytical Method Validation, San Diego, CA, 2-4 December
35 Top challenges for method validation (MV) Mass imbalance (desired to have assay + impurities within %) Solution stress Degradation products with very different UV responses, mass balance is often outside % Solutions: generate 5-20% degradation; set % for early stage development? However, outside % might indicate a real problem with the material (e.g., degradation, inorganic, volatile impurities) We encountered problems with degradation and inorganic impurities, which were revealed by low assays Recovery out of range Sample preparation (solubility, dilution ) Peak contamination from dirty glassware, mobile phase, column, or system... Matrix effect - any change in manufacture and quality of excipients, filter We experienced such changes (suppliers did not notify) and did time-consuming investigations Degradation IVT Analytical Method Validation, San Diego, CA, 2-4 December
36 Acknowledgments Lily Du Jessica Vazquez Oliver Taylor (2014 summer intern from New York University) Natalia Luneva Shaun Mendonsa Ken Cohen IVT Analytical Method Validation, San Diego, CA, 2-4 December
37 Backup IVT Analytical Method Validation, San Diego, CA, 2-4 December
38 Principles of CAD Nebulization Evaporation Particle Monitoring Particle Charging 38
39 Corona Charged Aerosol Detector (CAD) No analyte is actually ionized by CAD CAD is a Quadratic Response Detector Linear-like over short ranges and low concentrations Signal increases with increased organic content Basic ph mobile phase will result in low S/N Tetrahydrofuran, hexanes and halogenated solvents like dichloromethane, and chloroform may require heated nebulization Corona Plus 39
40 HPLC Method Translation (Conversion) Ref: Ronald E. Majors, Method Translation in Liquid Chromatography, LCGC IVT Analytical Method Validation, San Diego, CA, 2-4 December
41 Non-Volatile to Volatile Buffer Conversion for LC-MS Structural Identification Replace phosphate with volatile buffer from list below based on ph Use the same column, temp, organic, gradient, flow rate, etc. Perform minor fine tuning as needed to get equivalent selectivity Gradient shape, % B, flow rate, temp, etc. Phosphate Buffer ph Volatile Buffer 2.0 TFA 3.0 Formic Acid 4.0 Acetic Acid 5.0 Ammonium Acetate (acetate) 6.0 Ammonium Bicarbonate (carbonate, 1) 7.0 Ammonium Acetate (ammonium) 8.0 Ammonium Hydroxide 9.0 Ammonium Bicarbonate (ammonium) 41
42 Top challenges for method validation - How much MV needs to be done? IQ paper recommendations 42
Application Note. Author. Abstract. Pharmaceutical QA/QC. Vinayak A.K Agilent Technologies Bangalore, India
QbD Based Method Development on an Agilent 129 Infinity UHPLC System Combined with a Seamless Method Transfer to HPLC Using Intelligent System Emulation Technology Application Note Pharmaceutical QA/QC
More information7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.
7. Stability indicating analytical method development and validation of and in capsule dosage form by HPLC. 7.1 INSTRUMENTS AND MATERIALS USED 7.1.1 INSTRUMENTS 1. Shimadzu LC-2010 CHT with liquid chromatograph
More informationDEVELOPMENT AND VALIDATION OF NEW ANALYTICAL METHOD FOR BIOACTIVE COMPOUNDS
OF Ph.D. THESISS ENTITLED DEVELOPMENT AND VALIDATION OF NEW ANALYTICAL METHOD FOR BIOACTIVE COMPOUNDS SUBMITTED TO KADI SARVA VISHWAVIDYALAYA, GANDHINAGAR, GUJARAT, INDIA FOR THE DEGREE OF DOCTOR OF PHILOSOPHY
More informationStreamlining the Analysis of Oral Contraceptives Using the ACQUITY UPLC H-Class System
Streamlining the Analysis of Oral Contraceptives Using the ACQUITY UPLC H-Class System Margaret Maziarz, Sean M. McCarthy, Michael D. Jones, and Warren B. Potts Waters Corporation, Milford, MA, USA A P
More informationDETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
CHAPTER 9 DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY CHAPTER 9 Determination of drug release during
More informationVALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION
VALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION Andrew J. Aubin and Tanya L. Jenkins Waters Corporation, Milford, MA, USA INTRODUCTION Benzocaine (4-Aminobenzoic
More informationThe Use of the ACQUITY QDa Detector for a Selective, Sensitive, and Robust Quantitative Method for a Potential Genotoxic Impurity
The Use of the ACQUITY QDa Detector for a Selective, Sensitive, and Robust Quantitative Method for a Potential Genotoxic Impurity Janet Hammond Waters Corporation, Wilmslow, UK APPLICATION BENEFITS High
More informationLC and LC/MS Column Selection Flow Chart
LC and LC/MS Column Selection Flow Chart To use the column selection diagram below, simply follow the path for your analyte and mobile phase. At the far right, follow your final column selection to the
More informationChapter 4: Verification of compendial methods
Chapter 4: Verification of compendial methods Introduction In order to ensure accurate and reliable test results, the quality control laboratory (QCL) needs to use analytical methods (and accompanying
More informationA Quality by Design (QbD) Based Method Development for the Determination of Impurities in a Peroxide Degraded Sample of Ziprasidone
A Quality by Design (QbD) Based Method Development for the Determination of Impurities in a Peroxide Degraded Sample of Ziprasidone Mia Summers and Kenneth J. Fountain Waters Corporation, 34 Maple St.,
More informationTEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD
APPENDIX V TEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD Validating Chromatographic Methods. By David M. Bliesner Copyright 2006 John Wiley & Sons, Inc. 159 160 APPENDIX V Title: Effective: Document No:
More informationRoutine MS Detection for USP Chromatographic Methods
Daniel S. Root, Thomas E. Wheat, and Patricia McConville Waters Corporation, Milford, MA, USA APPLICATION BENEFITS This approach enables mass spectral analysis of peaks directly from unmodified USP HPLC
More informationRapid Screening and Confirmation of Melamine Residues in Milk and Its Products by Liquid Chromatography Tandem Mass Spectrometry
Rapid Screening and Confirmation of Melamine Residues in Milk and Its Products by Liquid Chromatography Tandem Mass Spectrometry Application Note Food Authors Jianqiu Mi, Zhengxiang Zhang, Zhixu Zhang,
More informationACD/AutoChrom Assisted Method Development for Challenging Separations. Vera Leshchinskaya February 7, 2018
ACD/AutoChrom Assisted Method Development for Challenging Separations Vera Leshchinskaya February 7, 2018 Introduction Resolution of isomeric species is one of the most challenging areas of separation
More informationDetermination of Carbonyl Compounds In Water by Dinitrophenylhydrazine Derivatization and HPLC/UV*
Determination of Carbonyl Compounds In Water by Dinitrophenylhydrazine Derivatization and HPLC/UV* EPA Method 8315A UCT Part Number: EUC1812M15 (Unendcapped C18-2000 mg/15 ml cartridge) March 2013 Method
More informationHow proteins separate on reverse-phase HPLC
1 Reverse Phase How proteins separate on reverse-phase HPLC RP chromatography separates proteins through the interaction of the hydrophobic foot of the protein with a nonpolar surface of the particle RP
More informationUPLC for Synthetic Peptides: A User`s Perspective
Tides 2007 Conference Las Vegas, May 23, 2007 UPLC for Synthetic Peptides: A User`s Perspective Holger Hermann, Jens Donath* Lonza AG, Switzerland Welcome to Lonza! One of the leading CMO Production facilities
More informationCHAPTER - IV. Acharya Nagarjuna University, Guntur 105
CHAPTER - IV Acharya Nagarjuna University, Guntur 105 A STABILITY-INDICATING LC METHOD FOR LENALIDOMIDE Lenalidomide, 3-(4-amino-1-oxo-3H-isoindol-2-yl) piperidine-2, 6-dione (fig. 4.1), is a novel oral
More informationUPLC Method Development and Validation
UPLC Method Development and Validation Rev. 2 2008 Waters Corporation Challenges of Method Development Methods are developed throughout the drug development process Samples vary in complexity Redundancy
More informationAgilent 1200 Infinity Series HDR DAD Impurity Analyzer System for the Quantification of Trace Level of Genotoxic Impurity
Agilent 12 Infinity Series HDR DAD Impurity Analyzer System for the Quantification of Trace Level of Genotoxic Impurity A case study with degraded omeprazole drug product Application Note Small Molecule
More informationValidated HPLC Methods
Validated HPLC Methods To Tweak or Not to Tweak Slide 4 Adjustments of operating conditions to meet system suitability requirements may be necessary. USP 23 p1776 Slide 5 001816S1.PPT What is the line
More informationVolume 6, Issue 2, January February 2011; Article-015
Research Article DEVELOPMENT AND VALIDATION OF A RP-HPLC METHOD FOR THE DETERMINATION OF DAPOXETINE HYDROCHLORIDE IN PHARMACEUTICAL FORMULATION USING AN EXPERIMENTAL DESIGN Pratik Mehta*, Ujjwal Sahoo,
More informationApplication Note. Author. Abstract. Pharmaceutical QA/QC. Siji Joseph Agilent Technologies, Inc. Bangalore, India
Effective use of pharmacopeia guidelines to reduce cost of chromatographic analysis Optimized, cost-effective HPLC analysis of atorvastatin by varying column dimensions within the USP allowed limts
More informationDissolution Test 5 was validated using a Zodiac C18 brand of L1 column. The typical retention time for atorvastatin is about min.
Atorvastatin Calcium Tablets Type of Posting Posting Date 25 Jan 2019 Official Date 01 Feb 2019 Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance In accordance with the Rules
More informationUSP Method Transfer and Routine Use Analysis of Irbesartan Tablets from HPLC to UPLC
USP Method Transfer and Routine Use Analysis of Tablets from HPLC to UPLC Aparna Chavali, Tanya Jenkins and Patricia McConville Waters Corporation, 34 Maple Street, Milford, MA USA APPLICATION BENEFITS
More informationAdditionally, minor editorial changes have been made to update the monograph to current USP style.
Extended-Release Tablets Type of Posting Revision Bulletin Posting Date 27 Oct 2017 Official Date 01 Nov 2017 Expert Committee Chemical Medicines Monographs 4 Reason for Revision Compliance In accordance
More information2.1 2,3 Dichloro Benzoyl Cyanide (2,3 DCBC) and survey of. manufactured commonly for the bulk drug industry, few references were
. Introduction.,3 Dichloro Benzoyl Cyanide (,3 DCBC) and survey of analytical methods,3-dcbc substance, is the although advanced intermediate,3-dcbc is a of lamotrigine well-known bulk drug chemical manufactured
More informationValidation of Stability-Indicating RP-HPLC Method for the Assay of Ibrutinib in Pharmaceutical Dosage form
Validation of Stability-Indicating RP-HPLC Method for the Assay of Ibrutinib in Pharmaceutical Dosage form 8.1 Introduction Ibrutinib (IBR) is an anticancer drug targeting B-cell malignancies (blood cancer
More informationpenta-hilic UHPLC COLUMNS
penta-hilic UHPLC COLUMNS penta-hilic Highly retentive, proprietary penta-hydroxy-ligand Excellent peak shape for polar compounds with a variety of functional groups: acids, bases, zwitterions strong and
More informationImpact factor: 3.958/ICV: 4.10 ISSN:
Impact factor: 3.958/ICV: 4.10 ISSN: 0976-7908 99 Pharma Science Monitor 9(4), Oct-Dec 2018 PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES Journal home page: http://www.pharmasm.com
More informationIdentification, Quantitation and Control of Trace Level Genotoxic Impurities in Organic Synthesis Intermediates and Final Products
Identification, Quantitation and Control of Trace Level Genotoxic Impurities in Organic Synthesis Intermediates and Final Products CoSMoS Aug 2011 GSK Internal Control Strategy Process Control Strategy
More informationCHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW
75 CHAPTER 3 DEVELOPMENT AND APPLICATION OF STABILITY-INDICATING HPLC METHOD FOR THE DETERMINATION OF NEVIRAPINE AND ITS IMPURITIES IN COMBINATION DRUG PRODUCT 3.1 INTRODUCTION OF DOSAGE FORM AND LITERATURE
More informationSTABILITY INDICATING METHOD OF RELATED IMPURITIES IN VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS
Issn No: 976-39 RESEARCH ARTICLE STABILITY INDICATING METHOD OF RELATED IMPURITIES IN VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS CHETLAPALLI SATYA SRINIVAS 1, P.RENUKA DEVI 2 and GAMPA VIJAYAKUMAR*
More informationQuantification of growth promoters olaquindox and carbadox in animal feedstuff with the Agilent 1260 Infinity Binary LC system with UV detection
Quantification of growth promoters olaquindox and carbadox in animal feedstuff with the Agilent 126 Infinity Binary LC system with UV detection Application Note Food Author Srividya Kailasam Agilent Technologies,
More informationToo Polar for Reversed Phase What Do You Do?
Too Polar for Reversed Phase What Do You Do? June 20, 2013 Mark Powell Columns and Consumables Technical Support Page 1 C8 or C18 Doesn t Always Do the Job Typical reversed phase conditions involve water/buffer
More informationInt. J. Pharm. Sci. Rev. Res., 30(2), January February 2015; Article No. 09, Pages: 63-68
Research Article Stability indicating RP-HPLC Method for Determination of FexoFenadine Hydrochloride and its Related Substances in Active Pharmaceutical Substance Abhay Gupta* 1, Dr. Birendra Srivastava,
More informationSimultaneous estimation of amitryptyline and chlordiazepoxide by RP-HPLC method
IJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page: ISSN: 2320-2831 Research article Open Access Simultaneous estimation of amitryptyline and chlordiazepoxide by RP-HPLC method Dr.R.Srinivasan*, K.Lurdhu
More informationThis method describes the identification of the following prohibited colorants in cosmetic products:
A. IDENTIFICATION BY TLC 1. SCOPE AND FIELD OF APPLICATION This method describes the identification of the following prohibited colorants in cosmetic products: Names C I number Pigment Orange 5 12075 Metanil
More informationHigh-Resolution Sampling 2D-LC for Pharmaceutical Impurity Analysis
High-Resolution Sampling D-LC for Pharmaceutical Impurity Analysis Detection of Impurities Hidden Under the API Peak at Relevant Levels Application Note Small Molecule Pharmaceuticals and Generics Authors
More informationJournal of Pharmaceutical and Biomedical Analysis Letters. Analysis Letters
Naga Jyothi. C et al, JPBMAL, 2015, 3(1): 242 246 ISSN: 2347-4742 Journal of Pharmaceutical and Biomedical Analysis Letters Journal Home Page: www.pharmaresearchlibrary.com/jpbmal Research Article Open
More informationIDENTIFICATION OF STEROIDS IN COSMETIC PRODUCTS BY TLC AND HPLC 1 02/12/2005 ACM 007 A. THIN LAYER CHROMATOGRAPHY (TLC)
Document A. THIN LAYER CHROMATOGRAPHY (TLC) 1. SCOPE AND FIELD OF APPLICATION The method describes the identification of hydrocortisone acetate, dexamethasone, betamethasone, betamethasone 17-valerate
More informationBRIEFING. (EXC: K. Moore.) RTS C Propylparaben C 10 H 12 O Benzoic acid, 4 hydroxy, propyl ester; Propyl p hydroxybenzoate [ ].
BRIEFING Propylparaben. The European Pharmacopoeia is the coordinating pharmacopeia for the international harmonization of the compendial standards for the Propylparaben monograph, as part of the process
More informationDeveloping Analytical Chromatographic Methods for Pharmaceutical Stability Investigations
Developing Analytical Chromatographic Methods for Pharmaceutical Stability Investigations Warren B Potts III Senior Director Americas Marketing Warren_potts@waters.com 2017 Waters Corporation 1 Outline
More informationAnalysis of DNPH-derivatized Aldehydes and Ketones using the Agilent 1220 Infinity LC System with Diode Array Detector
Analysis of DNPH-derivatized Aldehydes and Ketones using the Agilent Infinity LC System with Diode Array Detector Application Note Author Sonja Schneider Agilent Technologies, Inc. Waldbronn, Germany [mau]
More informationCHAPTER 1 Role of Bioanalytical Methods in Drug Discovery and Development
UMMERY The need to develop new analytical methods for assurance of quality, safety and efficacy of drugs and pharmaceuticals is quite important because of their use not only as health care products but
More informationASEAN GUIDELINES FOR VALIDATION OF ANALYTICAL PROCEDURES
ASEAN GUIDELINES FOR VALIDATION OF ANALYTICAL PROCEDURES Adopted from ICH Guidelines ICH Q2A: Validation of Analytical Methods: Definitions and Terminology, 27 October 1994. ICH Q2B: Validation of Analytical
More informationDevelopment and Validation of a HPLC Method for Chlorphenamine Maleate Related Substances in Multicomponents Syrups and Tablets
Development and Validation of a HPLC Method for Chlorphenamine Maleate Related Substances in s Syrups and Tablets Larisa Alagić-Džambić*, Midhat Vehabović, Edina Čekić, Mirsad Džambić Development Department,
More informationMethod Development and Validation Of Prasugrel Tablets By RP- HPLC
Method Development and Validation Of Prasugrel Tablets By RP- HPLC K.Sonia*, Ndwabe Hamunyare, K.Manikandan Department of Pharmaceutical Analysis, SRM College of Pharmacy, SRM University, Kattankulathur,
More informationMashhour Ghanem 1 and Saleh Abu-Lafi 2 * ABSTRACT ARTICLE INFO
. Journal of Applied Pharmaceutical Science Vol. 3 (10), pp. 051-058, October, 2013 Available online at http://www.japsonline.com DOI: 10.7324/JAPS.2013.31009 ISSN 2231-3354 Validation of a Stability-Indicating
More informationValue of Eclipse Plus C18 and ph Selectivity to Analyze Amine-Containing Drugs
Value of Eclipse Plus C18 and ph Selectivity to Analyze Ae-Containing Drugs Application Pharmaceuticals Authors John W. Henderson Jr., William J. Long, and Cliff Woodward Agilent Technologies 285 Centerville
More informationA RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF PARA- PHENYLENEDIAMINE IN PURE FORM AND IN MARKETED PRODUCTS
A RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF PARA- PHENYLENEDIAMINE IN PURE FORM AND IN MARKETED PRODUCTS CH.MOUNIKA*, M.KINNERA Research Article SIR.C.R.REDDY COLLEGE OF PHARMACEUTICAL SCIENCES, ELURU.
More informationAppendix II- Bioanalytical Method Development and Validation
A2. Bioanalytical method development 1. Optimization of chromatographic conditions Method development and optimization of chromatographic parameters is of utmost important for validating a method in biological
More informationRevision Bulletin 27 Jan Feb 2017 Non-Botanical Dietary Supplements Compliance
Niacin Extended-Release Tablets Type of Posting Posting Date Official Date Expert Committee Reason for Revision Revision Bulletin 27 Jan 2017 01 Feb 2017 Non-Botanical Dietary Supplements Compliance In
More informationCYCLOSERINE Final text for addition to The International Pharmacopoeia. (November 2008) CYCLOSERINUM CYCLOSERINE
December 2008 CYCLOSERINE Final text for addition to The International Pharmacopoeia (November 2008) This monograph was adopted at the Forty-third WHO Expert Committee on Specifications for Pharmaceutical
More informationDevelopment And Validation Of Rp-Hplc Method For Determination Of Velpatasvir In Bulk
International Journal of Engineering Science Invention (IJESI) ISSN (Online): 2319 6734, ISSN (Print): 2319 6726 www.ijesi.org PP. 36-41 Development And Validation Of Rp-Hplc Method For Determination Of
More informationRapid, Reliable Metabolite Ratio Evaluation for MIST Assessments in Drug Discovery and Preclinical Studies
Rapid, Reliable Metabolite Ratio Evaluation for MIST Assessments in Drug Discovery and Preclinical Studies Jonathan Danaceau, Erin Chambers, and Kenneth J. Fountain Waters Corporation, Milford, MA, USA
More informationNEVIRAPINE ORAL SUSPENSION Final text for addition to The International Pharmacopoeia (February 2009)
February 2009. NEVIRAPINE ORAL SUSPENSION Final text for addition to The International Pharmacopoeia (February 2009) This monograph was adopted at the Forty-third WHO Expert Committee on Specifications
More information(RS)-2-(4-isobutyrylphenyl)propanoic acid Ibuprofen Impurity J
Reference Material Product Information Sheet Epichem's Quality System conforms to ISO9001:2015 as certified by ECAAS Pty Ltd - Certification number 616061. Name BP Name Synonym(s) O (RS)-2-(4-isobutyrylphenyl)propanoic
More informationWelcome to our E-Seminar: Choosing HPLC Columns for Faster Analysis Smaller and Faster
Welcome to our E-Sear: Choosing HPLC Columns for Faster Analysis Smaller and Faster High Throughput/Fast LC Requires. Short columns 0 mm or shorter Small particle sizes. µm Rapid Resolution or new.8 µm
More informationPart 2. Overview of HPLC Media
Part 1. General Chromatographic Theory Part 2. Overview of HPLC Media Part 3. The Role of the Mobile Phase in Selectivity Part 4. Column Care and Use 1 HPLC Particle Technology Core-Shell Particle Fully
More informationfor Acclaim Mixed-Mode HILIC-1 Column
for Acclaim Mixed-Mode HILIC-1 Column Product Manual for ACCLAIM Mixed-Mode HILIC-1 Page 1 of 17 Product Manual for ACCLAIM Mixed-Mode HILIC-1 Column 5µm, 4.6 x 250mm, P/N 066844 5µm, 4.6 x 150mm, P/N
More informationWhat actually are dietary supplements? They are consumed in large quantities, but they
An Executive Summary Chromatographic Testing of Dietary Supplements following United States Pharmacopeia Monograph Methods Anita Piper Dr. Stephan Altmaier Markus Burholt Michael Schulz Dr. Patrik Appelblad
More informationA Fast and Sensitive Method for Residual Hydrazine Analysis in Pharmaceutical Samples
A Fast and Sensitive Method for Residual Hydrazine Analysis in Pharmaceutical Samples Vera Leshchinskaya, Priscilla Richberg, Yury Zelechonok*, and Anne Kelly Bristol Myers Squibb Company, P.O.BOX 4000,
More informationSravani and Haritha Indian Journal of Research in Pharmacy and Biotechnology ISSN: (Print) ISSN: (Online)
A new development and validated RP-HPLC method for the assay and related substances of Itraconazole in capsule dosage form Sarvani Paruchuri*, Haritha Pavani K Nimra College of Pharmacy, Vijayawada, Andhra
More informationProduct Bulletin. ACE LC/MS and Rapid Analysis HPLC Columns. HPLC Columns
Product Bulletin HPLC Columns ACE LC/MS and Rapid Analysis HPLC Columns 0 mm, 30 mm, 35 mm and 50 mm column lengths.0,., 3.0, 4.0 and 4.6 mm column diameters Configured for High Sample Throughput Specially
More informationThe Low-Temperature Evaporative Light-Scattering Detector (LT-ELSD)
The Low-Temperature Evaporative Light-Scattering Detector (LT-ELSD) Basically all compounds which are less volatile than the mobile phase can be detected. Detection is based on a Universal property of
More informationAnalysis of Stachydrine in Leonurus japonicus Using an Agilent ZORBAX RRHD HILIC Plus Column with LC/ELSD and LC/MS/MS
Analysis of Stachydrine in Leonurus japonicus Using an Agilent ZORBAX RRHD HILIC Plus Column with LC/ELSD and LC/MS/MS Application Note Traditional Chinese Medicine Author Rongjie Fu Agilent Technologies
More informationThe Secrets of Rapid HPLC Method Development. Choosing Columns for Rapid Method Development and Short Analysis Times
The Secrets of Rapid HPLC Method Development Choosing Columns for Rapid Method Development and Short Analysis Times Rapid Analysis Is More Than Run Time It is developing a method to meet a goal and developing
More informationpenta-hilic UHPLC COLUMNS
penta-hilic UHPLC COLUMNS Highly retentive, proprietary penta-hydroxy-ligand penta-hilic Excellent peak shape for polar compounds with a variety of functional groups: acids, bases, zwitterions strong and
More informationJournal of Drug Delivery and Therapeutics
Available online on 15.01.2018 at http://jddtonline.info Journal of Drug Delivery and Therapeutics Open Access to Pharmaceutical and Medical Research 2011-17, publisher and licensee JDDT, This is an Open
More informationRevision Bulletin 29 Dec Jan 2018 Non-Botanical Dietary Supplements Compliance
Niacin Extended-Release Tablets Type of Posting Posting Date Official Date Expert Committee Reason for Revision Revision Bulletin 29 Dec 2017 01 Jan 2018 Non-Botanical Dietary Supplements Compliance In
More informationWork plan & Methodology: HPLC Method Development
Work plan & Methodology: HPLC Method Development The HPLC analytical Method developed on the basis of it s chemical structure, Therapeutic category, Molecular weight formula, pka value of molecule, nature,
More informationSECOBARBITAL Latest Revision: February 15, 1999
SECOBARBITAL Latest Revision: February 15, 1999 1. SYNONYMS CFR: Secobarbital CAS #: Free acid: 76-73-3 Sodium salt: 309-43-3 Other Names: 5-(1-Methylbutyl)-5-(2-propenyl)-2,4,6-(1H,3H,5H)-pyrimidinetrione
More informationserve the goal of analytical lmethod Its data reveals the quality, reliability and consistency of
Analytical method validation By Juree Charoenteeraboon, Ph.D Analytical method Goal consistent, reliable and accurate data Validation analytical method serve the goal of analytical lmethod Its data reveals
More informationwith diode array detection
Application Note Small Molecule Pharmaceuticals Analysis of Tween 8 by highperformance liquid chromatography with diode array detection Authors Jianxin Yu, Scott Citrowske, Nikki Carlson, and Jacob Strange
More informationDevelopment of Validated Analytical Method of Mefenamic Acid in an Emulgel (Topical Formulation)
Development of Validated Analytical Method of Mefenamic Acid in an Emulgel (Topical Formulation) TEENA OSWAL*, DR.SURYAKANT BHOSALE, DR. SONALI NAIK MET Institute Of Pharmacy Met Complex, Bandra Reclamation,
More informationRapid and simultaneous determination of paracetamol, ibuprofen and related impurity of ibuprofen by UPLC/DAD
Pharmaceutical Sciences Asia Pharm Sci Asia 2018; 45 (4), 213-220 Research Article DOI :10.29090/psa.2018.04.017.0056 Rapid and simultaneous determination of paracetamol, ibuprofen and related impurity
More informationDilution(*) Chromatography
WA20264 Poster # 184, HPLC 2002, Montreal, 4-5 June 2002 At-Column Column-Dilution for Preparative Dilution(*) Chromatography Cecilia Mazza, Jie Cavanaugh, Ziling Lu,Tom Sirard,Tom Wheat and Uwe Neue Waters
More information637. Thiamethoxam. HPLC method
637. Thiamethoxam HPLC method CIPAC Collaborative Trial according to CIPAC Information Sheet N o 293 Dr. Sven Adolph Syngenta Crop Protection Münchwilen AG CH-4333 Münchwilen Switzerland May 212 page 1
More informationKEYWORDS: Acetaminophen, Doxylamine succinate, Dextromethorphan hydrobromide.
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 3 Issue 7 July 2014 PP.08-12 Analytical method development and validation of acetaminophen,
More informationcontents of the currently official monograph. Please refer to the current edition of the USP NF for official text.
Isosorbide Mononitrate Extended-Release Tablets Type of Posting Posting Date Targeted Official Date Notice of Intent to Revise 28 Sep 2018 To Be Determined, Revision Bulletin Expert Committee Chemical
More informationSuccessfully Scaling and Transferring HPLC and UPLC Methods
Successfully Scaling and Transferring HPLC and UPLC Methods Esa Lehtorinne Esa_Lehtorinne@waters.com Tel: +358-9-5659 6288 Fax: +358-9-5659 6282 Waters Finland Kutomotie 16 00380 Helsinki 2013 Waters Corporation
More informationHigh Performance Liquid Chromatography
Updated: 3 November 2014 Print version High Performance Liquid Chromatography David Reckhow CEE 772 #18 1 HPLC System David Reckhow CEE 772 #18 2 Instrument Basics PUMP INJECTION POINT DETECTOR COLUMN
More informationHigh Performance Liquid Chromatography
Updated: 3 November 2014 Print version High Performance Liquid Chromatography David Reckhow CEE 772 #18 1 HPLC System David Reckhow CEE 772 #18 2 1 Instrument Basics PUMP INJECTION POINT DETECTOR COLUMN
More informationADVANTAME. Not less than 97.0% and not more than 102.0% on the anhydrous basis. Sweetener, flavour enhancer
ADVANTAME SYNONYMS INS No. 969 Prepared at the 80 th JECFA (2015), published in FAO JECFA Monographs 17 (2015), superseding tentative specifications prepared at 77 th JECFA (2013). An ADI of 0-5 mg/kg
More informationARTEMETHER AND LUMEFANTRINE ORAL SUSPENSION:Final text for addition to The International Pharmacopoeia (November 2008)
November 2008 ` ARTEMETER AND LUMEFANTRINE RAL SUSPENSIN:Final text for addition to The International Pharmacopoeia (November 2008) Category. Antimalarial. Storage. Artemether and lumefantrine oral suspension
More informationApplication Note. Author. Abstract. Xinlei Yang Agilent Technologies Co. Ltd Shanghai, China
Rapid Deteration of Eight Related Aromatic Acids in the p-phthalic Acid Mother Liquid Using an Agilent 126 Infinity LC System and an Agilent Poroshell 12 SB-C18 Column Application Note Author Xinlei Yang
More informationFrank Steiner, Michael Heidorn, and Markus M. Martin Thermo Fisher Scientific, Germering, Germany
Generic Method Approach for Pharmaceutical Drug Discovery and Development using Reversed-Phase Hydrophilic Interaction Liquid Chromatography with Universal Charged Aerosol Detection Frank Steiner, Michael
More informationOptical Isomer Separation Columns and Packing Materials
02 Optical Isomer Separation s and Packing Materials CHIRAL ART----------------------------------- 26~29 YMC CHIRAL NEA (R), (S)-----------------------30 YMC CHIRAL CD BR------------------------------31
More informationBUFOTENINE Latest Revision: August 16, 2005
BUFOTENINE Latest Revision: August 16, 25 H N HO N CH 3 CH 3 1. SYNONYMS CFR: Bufotenine CAS #: Base: 487-93-4 Other Names: N,N-dimethylserotonin, 5-hydroxy-N,N-dimethyltryptamine, mappine 2. CHEMICAL
More informationIntegrated approach to HPLC method development: Using all the tools in the chromatographer s toolbox
Integrated approach to HPLC method development: Using all the tools in the chromatographer s toolbox Rosario LoBrutto Pharmaceutical and Analytical Development Novartis Pharmaceuticals Overall Strategy
More informationReversed Phase Solvents
Part 1. General Chromatographic Theory Part 2. verview of HPLC Media Part 3. The Role of the Mobile Phase in Selectivity Part 4. Column Care and Use Reversed Phase Solvents 2 Solvents for RP Chromatography
More informationImplementation of Methods Translation between Liquid Chromatography Instrumentation
Implementation of Methods Translation between Liquid Chromatography Instrumentation Michael D. Jones, Peter Alden, Kenneth J. Fountain, and Andrew Aubin Waters Corporation, Milford, MA, U.S. APPLICATION
More informationComparison of different aqueous mobile phase HPLC techniques
June 009 ewsletter Pharmaceutical Analysis: What is Your Problem? SIELC Technologies, Inc., Prospect Heights, IL 0070 Pharmaceutical analysis involves liquid chromatography of various compounds, from active
More informationDetermination of Beta-Blockers in Urine Using Supercritical Fluid Chromatography and Mass Spectrometry
Determination of Beta-Blockers in Urine Using Supercritical Fluid Chromatography and Mass Spectrometry Application Note Doping Control Authors Prof. Maria Kristina Parr Freie Universität Berlin Institute
More informationcontents of the currently official monograph. Please refer to the current edition of the USP NF for official text.
Metformin Hydrochloride Extended-Release Tablets Type of Posting Posting Date Targeted Official Date Notice of Intent to Revise 28 Sept 2018 To Be Determined, Revision Bulletin Expert Committee Chemical
More informationEffects of Aqueous Sample Content and Aqueous Co-Solvent Composition on UPC 2 Separation Performance
Effects of Aqueous Sample Content and Aqueous Co-Solvent Composition on UPC 2 Separation Performance Christopher Knappy, 1 Norman W Smith, 1 Arundhuti Sen, 1 Paul D Rainville, 2 and Robert S Plumb 2 1
More informationStability indicating RP-HPLC method for determination of azilsartan medoxomil in bulk and its dosage form
IJPAR Vol.3 Issue 4 Oct-Dec-2014 Journal Home page: ISSN: 2320-2831 Research article Open Access Stability indicating RP-HPLC method for determination of azilsartan medoxomil in bulk and its dosage form
More informationPackings for HPLC. Packings for HPLC
Summary of packings for HPLC In analytical HPLC, packings with particle sizes of 3 to 10 µm are preferred. For preparative separation tasks, also particles with diameters larger than 10 µm are applied.
More information[ a ppl ic at ion no t e ]
[ a ppl ic at ion no t e ] Fast A nalysis of A ldehydes and K etones by A C Q U I T Y U P L C Mark E. Benvenuti Waters Corporation, Milford, MA, USA INT RO DUC T ION Aldehydes and ketones are products
More information